NYSE: MANEVeradermics Inc Stock
$68.80+8.82 (+14.7%)
Updated Apr 10, 2026
MANE Price
$68.80
Fair Value Price
N/A
Market Cap
$2.57B
52 Week Low
$32.00
52 Week High
$69.44
P/E
-0.61x
P/B
-21.23x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$83.37M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.08
Operating Cash Flow
-$72M
Beta
0.67
Next Earnings
May 15, 2026
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MANE's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MANE
Ranked#97 of 460
Ranked#97 of 460
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.76 | A | |
| $5.85 | A | |
| $194.20 | A |
Be the first to know about important MANE news, forecast changes, insider trades & much more!
MANE News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MANE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MANE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MANE is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
MANE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more MANE due diligence checks available for Premium users.
Valuation
MANE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.61x
Industry
27.82x
Market
29.91x
MANE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-21.23x
Industry
4.82x
MANE's financial health
Profit margin
Revenue
$0.0
Net Income
-$28.2M
Profit Margin
0%
MANE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$152.6M
Liabilities
$9.2M
Debt to equity
-0.08
MANE's short-term assets ($152.49M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MANE's short-term assets ($152.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MANE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MANE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$23.6M
Investing
-$109.8M
Financing
$149.5M
MANE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MANE vs Biotech Stocks
Veradermics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.